Kiora Pharmaceuticals (KPRX)

• Market cap: $7.83M
• 1 day: -0.47%
• 5 days: 5.97%
• 1 month: -7.79%
• 3 months: -19.32%
• 6 months: -30.84%
• Year to date: -40.5%
• 1 year: -39.32%
• 5 years: -99.84%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Employees: 12